NDAORALTABLETPriority Review
Approved
Dec 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
11
Mechanism of Action
Gonadotropin Releasing Hormone Receptor Antagonists
Pharmacologic Class:
Gonadotropin Releasing Hormone Receptor Antagonist
Clinical Trials (5)
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Started Jan 2025
72 enrolled
Recurrent Prostate CarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
Relugolix + Enzalutamide Study in High-Risk Prostate Cancer
Started Dec 2024
46 enrolled
Androgen Deprivation TherapyLocally Advanced Prostate Cancer
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
Started Dec 2024
33 enrolled
Prostate CancerAdvanced Prostate CancerHormone Sensitive Prostate Cancer
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
Started Oct 2024
30 enrolled
Prostate CAProstate Cancer (Adenocarcinoma)Prostate Cancer Surgery
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Started Aug 2024
70 enrolled
Prostate AdenocarcinomaStage IIB Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8
Loss of Exclusivity
LOE Date
Sep 29, 2037
140 months away
Patent Expiry
Sep 29, 2037